Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi Winthrop Industrie

Press release: Availability of the Q2 2025 Aide mémoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press release: Sanofi successfully prices €1.5 billion bond issue
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi completes acquisition of DR-0201
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Annual General Meeting of April 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Availability of the Q1 2025 Aide mémoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
From Sanofi Winthrop Industrie
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS